News Virpax Pharmaceuticals, Inc.

Equities

VRPX

US9282512063

Market Closed - Nasdaq Other stock markets 04:30:01 2024-06-04 pm EDT			5-day change	1st Jan Change
0.703 ^USD	-0.99%		-1.13%	-78.04%

May. 22	Maxim Downgrades Virpax Pharmaceuticals to Hold From Buy	MT
May. 15	Virpax Prices Public Offering of Shares, Warrants; Shares Tumble	MT

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Virpax Pharmaceuticals to Present at 2024 BIO International Convention	May. 30	AQ
Virpax® Pharmaceuticals to Present at 2024 BIO International Convention	May. 29	BU
Maxim Downgrades Virpax Pharmaceuticals to Hold From Buy	May. 22	MT
Virpax Prices Public Offering of Shares, Warrants; Shares Tumble	May. 15	MT
Top Premarket Decliners	May. 15	MT
Investors Await Key Inflation Data for April as US Futures Remain Flat in Wednesday's Premarket	May. 15	MT
Virpax Announces Pricing of $2.25 Million Public Offering	May. 15	BU
Virpax Pharmaceuticals Reports 2024 First Quarter Results and Recent Developments	May. 13	BU
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
Virpax Pharmaceuticals, Inc. Announces Resignation of Jeffrey Gudin as Chief Medical Officer and Executive Vice President	May. 02	CI
Virpax Announces Results of Maximum Tolerated Dose Study for Probudur	May. 01	AQ
Virpax Announces Results of Maximum Tolerated Dose Study for Probudur™	Apr. 30	BU
Virpax Pharmaceuticals, Inc. Announces Results of Maximum Tolerated Dose Study for Probudur	Apr. 30	CI
Virpax Pharmaceuticals Reports 2023 Year-End Results	Mar. 26	BU
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs	Mar. 15	MT
Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price	Feb. 28	AQ
Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price	Feb. 27	BU
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.	Feb. 27	BU
Virpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical Research	Feb. 07	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Virpax Pharmaceuticals, Inc.

Equities

VRPX

US9282512063

Summary

Filters